Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

They're Estrogen Receptor or ER, Progesterone Receptor, which is PR, and then HER2/neu. So estrogen and progesterone, most people have heard of because they're hormones that the body makes ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Greenwich LifeSciences (GLSI) announced the following update on FLAMINGO-01 open label safety data. The FLAMINGO-01 DSMB met twice in 2024, ...

17, 2025, explaining how the new drug combo has been approved for “hormone receptor-positive/human epidermal growth factor ...

The universal cell-cycle inhibitor p21 Cip1/WAF1 is phosphorylated and localized in the cytoplasm in Her2/neu-overexpressing breast cancers as a result of its physical association with the ...

Tumors, such as some breast and ovarian cancers, can express the marker HER2. HER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...

In close collaboration with the lab of Nai-Kong Cheung at MSK and Dane Wittrup at MIT, we have successfully applied this platform in three preclinical tumor models: GPA33 antigen (colorectal cancer); ...